Aeglea BioTherapeutics held its 2023 Annual Meeting of Stockholders and approved various proposals including the election of directors, ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm, approval of executive compensation, approval of an amendment to the company's certificate of incorporation for a reverse stock split, and approval of an amendment and restatement of the company's equity incentive plan.